Moderna, Inc.

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP
60770K107
SEDOL
BH3JLT8
CIK
0001682852
www.modernatx.com
LEI: 549300EI6OKH5K5Q2G38
©
Moderna is a Member of Themefolio
          Covid19-STX          
FIGI: BBG003PHHZT1
MRNA
Moderna, Inc.
GICS: - · Sektor: Healthcare · Sub-Sektor: Biotechnology
AI
PROFILER
NAME
Moderna, Inc.
ISIN
US60770K1079
TICKER
MRNA
MIC
XNAS
REUTERS
MRNA.OQ
BLOOMBERG
MRNA US
BUILD THEMEFOLIO IDEEN TEILEN DISKUTIEREN
HEBEL INVESTIEREN
Financial Intelligence
360° iHub Crowd ATH Tracker Index Tracker ETF TF Spicy X-Billboard
FÜR INVESTOREN
FÜR TRADER
Börsenhandel Warrants
TradingView ActivTrader MT4 MT5
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von ACCESS Newswire bereitgestellt.
Fr., 28.02.2025       Moderna
US60770K1079

mRESVIA® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for active immunization for the prevention...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Di., 25.02.2025       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESS Newswire / February 25, 2025 / Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences:TD Cowen 45th Annual Health Care Conference, on Wednesday, March 5th at 9:10am ETBarclays 27th Annual Global Healthcare Conference, on Tuesday, March 11th at 1:30pm ETA live webcast of ...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Fr., 14.02.2025       Moderna
US60770K1079

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizingReports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28)Expects 2025 revenue range of $1.5 to 2.5 b...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Mi., 29.01.2025       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESS Newswire / January 29, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 14, 2025 to report its fourth quarter and full year 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Fr., 24.01.2025       Moderna
US60770K1079

/ Moderna, Inc. (NASDAQ: MRNA) hat heute bekannt gegeben, dass das Unternehmen im Rahmen einer Ausschreibung den Zuschlag für die Belieferung der Europäischen Union (EU) sowie Norwegen und Nord-Mazedonien mit seinem COVID-19-mRNA-Impfstoff erhalten hat. Die daraus resultierende Vereinbarung, an der 17 Länder teilnehmen, sieht eine Be...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Fr., 17.01.2025       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from th...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Mo., 13.01.2025       Moderna
US60770K1079

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited)Updates 2025 expected revenue range to $1.5 to 2.5 billionExpects to reduce 2025 cash cost expenses by $1.0 billion with a plan for additional 2026 cost reductions of $0.5 billionUpdates 2025 expected ending cash balanc...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Mo., 25.11.2024       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:7th Annual Evercore ISI HealthCONx Conference, on Wednesday, December 4th at 1:20pm ETPiper Sandler 36th Annual Healthcare Conference, on Thursday, December 5th at 10:30am ETA live webcast of...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Di., 12.11.2024       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report based on the Company's reputation and commitment to innovation."We are honored to be recognized by BioSpace as the most desirable large employer in the life scien...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Fr., 08.11.2024       Moderna
US60770K1079

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringesCanada is the fourth jurisdiction to approve mRESVIA following approvals in the U.S., Europe, and QatarCAMBRIDGE, MA / ACCESSWIRE / November 8, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced Health Canad...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S